Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$21.58M, compared with -$9.31M a year earlier. Trailing-twelve-month EBITDA was -$69.83M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -154.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.58M-22.7% QoQ
- Last fiscal yearDec 2025
- -$57.56M-154.1% YoY
- LTMMar 2026
- -$69.83M-147.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -131.9% | +100.0% | +231.9 pp |
| 1 year | -154.1% | +100.0% | +254.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (57.56M) USD
- Year-over-year change
- -154.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.56M) | -154.1% |
| FY2024 | 2024-12-31 | (22.65M) | -245.5% |
| FY2023 | 2023-12-31 | (6.56M) | +39.1% |
| FY2022 | 2022-12-31 | (10.76M) | — |
EBITDA vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 EBITDA of -$69.83M is the 5th highest of the 11 companies compared; the peer median is -$73.95M.
- Its year-over-year change of -147.0% is the 10th highest of 11, against a peer median of +9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$6.26M | +84.1% | — | 8.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$45.49M | -75.7% | — | — |
| LTM Mar 2026 | -$46.56M | +46.6% | — | 67.3% | |
| LTM Mar 2026 | -$50.77M | +11.7% | — | — | |
| LTM Mar 2026 | -$69.83M | -147.0% | — | — | |
| LTM Mar 2026 | -$72.53M | +7.7% | — | 257.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | -$75.38M | -21.4% | — | — |
| LTM Mar 2026 | -$75.47M | +22.0% | — | 33540.9% | |
| LTM Mar 2026 | -$75.93M | +0.5% | — | 547.9% | |
| LTM Mar 2026 | -$84.35M | -214.9% | — | 142957.6% | |
| LTM Mar 2026 | -$111.97M | +23.4% | — | 999.5% | |
| Peer median (excluding AARD) | -$73.95M | +9.7% | — | 547.9% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 7.17M | 4.48M | 17.36M | 48.94M |
| Selling, General & Admin | 2.7M | 2.17M | 5.31M | 13.79M |
| Operating Expenses | 11.36M | 7.42M | 22.79M | 62.73M |
| Depreciation & Amortization | 110K | 97K | 16K | 36K |
| EBITDA | (10.76M) | (6.56M) | (22.65M) | (57.56M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (11.36M) | (7.42M) | (22.79M) | (62.73M) |
| Operating Margin | — | — | — | — |
| Interest Income | 120K | 1.42M | 2.41M | 5.14M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (2.2M) | 207K | 2.2M | 5.13M |
| Income Before Tax | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.63) | (0.34) | (0.95) | (2.64) |
| EPS (Diluted) | (0.63) | (0.34) | (0.95) | (2.64) |
| Weighted Avg Shares | 21.38M | 21.38M | 21.7M | 21.82M |
| Weighted Avg Shares (Diluted) | 21.38M | 21.38M | 21.7M | 21.82M |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.